Joshua Brody, MD
Joshua Brody, MD, director of the lymphoma immunotherapy program at Tisch Cancer Institute at Mount Sinai, spoke with Healio about exciting treatment advances, recently approved targeted and immunotherapeutic agents and areas of unmet needs in follicular lymphoma.
In this video, Brody discusses:
- Notable advances and FDA approvals, including lenalidomide (Revlimid, Bristol-Myers Squibb) combined with rituximab and copanlisib (Aliqopa, Bayer);
- "Miraculous" results in CAR T therapy for aggressive and acute lymphomas;
- Adjusting treatment for "early relapsers" with chemoimmunotherapy;
- Promising treatments in the pipeline and upcoming clinical trials for novel immunotherapies; and
- The urgent need to eliminate residual lymphoma in patients with new combinations of novel immunotherapies and conventional therapies.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.